Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Apr 24, 2021 10:44am
161 Views
Post# 33061450

RE:RE:A couple of "stupid" questions

RE:RE:A couple of "stupid" questions
RjM2018 wrote: P3 further reduces risk. Although we showed statistically signifcant effiacy and safety with 250mg & 200mg doses, the 150mg dose wasn't powered for statistical significance. There was a very clear signal that the 150mg dose could be stat. sig. efficacious. Phase 3 trial is an adaptive design, in that they will study lower doses (like, 200mg, 150mg, 125/100mg) to find the lowest effective dose for go-to-market over 6 weeks vs 2 weeks for phase 2b.

Risks is that because the duration of treatment is 3x longer, AEs could arise...




Agreed RJM.

We have both positives and negatives at play.
To your point, duration is longer and new to OTENA ... so we don't know what to expect there.

But ...

We also have some work going on right now to better pinpoint where the drug might fail.
If we can get it down to 125 or even 100, that will play in our favour - with less active ingredient at only once per day, then we have reduced adverse effects.
Extended trial period could also be a positive thing w.r.t. H2S as we might see beyond its protective nature and into its ability to repair. 

That's where the excitement comes in for the future of H2S drugs.  Repair would show potential when combined with other drugs like an Alzheimer's drugs (for example) - not just protection but all out self-repair.  Fingers crossed.
<< Previous
Bullboard Posts
Next >>